Payment overview · 2025
General Payments
$355.41
12 reported records · 5 companies
Healthcare provider profile · identity verified
Samer S. Othman, MD
Allopathic & Osteopathic Physicians|Internal Medicine · SAN LUIS OBISPO, CA · NPI 1437476439
Verified facts
What the public records show
CMS Open Payments records show Samer S. Othman, MD received $355.41 in general payments during 2025 across 12 reported records.
VERTEX PHARMACEUTICALS INCORPORATED accounted for 34.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $123.34 | 34.7% | 4 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $80.97 | 22.8% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $65.18 | 18.3% | 3 | 2025 |
| Electronic Waveform Lab, Inc. | Unresolved — no canonical attribution shown | $49.52 | 13.9% | 3 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $36.40 | 10.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $355.41 | 12 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $123.34 | 4 | 2025 |
Source payment records
|
|||||
| ETERNA Normalized: eterna |
Device | Abbott Laboratories | $80.97 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $65.18 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $65.18 | 3 | 2025 |
Source payment records
|
|||||
| WaveWriter Alpha Prime 16 Normalized: wavewriter alpha prime 16 |
Device | Boston Scientific Corporation | $36.40 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 1727 | 206 |
| Gabapentin | Gabapentin | 1196 | 195 |
| Atorvastatin Calcium | Atorvastatin Calcium | 1022 | 98 |
| Eliquis | Apixaban | 602 | 57 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 552 | 69 |
| Furosemide | Furosemide | 529 | 63 |
| Levothyroxine Sodium | Levothyroxine Sodium | 473 | 61 |
| Amlodipine Besylate | Amlodipine Besylate | 422 | 57 |
| Tramadol Hcl | Tramadol Hcl | 354 | 54 |
| Pantoprazole Sodium | Pantoprazole Sodium | 346 | 64 |
| Metformin Hcl | Metformin Hcl | 328 | 40 |
| Metoprolol Tartrate | Metoprolol Tartrate | 316 | 34 |
| Baclofen | Baclofen | 307 | 40 |
| Xarelto | Rivaroxaban | 289 | 16 |
| Escitalopram Oxalate | Escitalopram Oxalate | 287 | 26 |
| Lisinopril | Lisinopril | 253 | 36 |
| Pregabalin | Pregabalin | 239 | 29 |
| Tamsulosin Hcl | Tamsulosin Hcl | 235 | 42 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 218 | 35 |
| Donepezil Hcl | Donepezil Hcl | 213 | 17 |
| Mirtazapine | Mirtazapine | 210 | 27 |
| Buprenorphine | Buprenorphine | 207 | 36 |
| Levetiracetam | Levetiracetam | 204 | 26 |
| Divalproex Sodium | Divalproex Sodium | 201 | 22 |
| Duloxetine Hcl | Duloxetine Hcl | 193 | 26 |
| Quetiapine Fumarate | Quetiapine Fumarate | 187 | 25 |
| Potassium Chloride | Potassium Chloride | 181 | 25 |
| Losartan Potassium | Losartan Potassium | 180 | 32 |
| Clopidogrel | Clopidogrel Bisulfate | 179 | 23 |
| Dilt-Xr | Diltiazem Hcl | 179 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 179 | 29 |
| Famotidine | Famotidine | 167 | 14 |
| Carvedilol | Carvedilol | 163 | 30 |
| Fluoxetine Hcl | Fluoxetine Hcl | 151 | 11 |
| Jardiance | Empagliflozin | 146 | 13 |
| Metoprolol Succinate | Metoprolol Succinate | 146 | 23 |
| Oxycodone Hcl | Oxycodone Hcl | 146 | 29 |
| Lidocaine | Lidocaine | 142 | 36 |
| Diclofenac Sodium | Diclofenac Sodium | 135 | 46 |
| Sertraline Hcl | Sertraline Hcl | 130 | 20 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 120 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 116 | 13 |
| Naloxone Hcl | Naloxone Hcl | 113 | 111 |
| Omeprazole | Omeprazole | 113 | 20 |
| Celecoxib | Celecoxib | 106 | 16 |
| Simvastatin | Simvastatin | 106 | 16 |
| Methocarbamol | Methocarbamol | 102 | 21 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 98 | 15 |
| Risperidone | Risperidone | 95 | suppressed |
| Spironolactone | Spironolactone | 91 | 15 |
| Amitriptyline Hcl | Amitriptyline Hcl | 86 | suppressed |
| Finasteride | Finasteride | 86 | 17 |
| Meloxicam | Meloxicam | 86 | 22 |
| Lorazepam | Lorazepam | 85 | 16 |
| Methadone Hcl | Methadone Hcl | 83 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 78 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 78 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 78 | 17 |
| Aripiprazole | Aripiprazole | 76 | suppressed |
| Memantine Hcl | Memantine Hcl | 76 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 72 | 11 |
| Morphine Sulfate | Morphine Sulfate | 72 | 11 |
| Januvia | Sitagliptin Phosphate | 69 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 68 | suppressed |
| Ibuprofen | Ibuprofen | 68 | 15 |
| Olanzapine | Olanzapine | 68 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 67 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 67 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 64 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 64 | suppressed |
| Clonazepam | Clonazepam | 63 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 60 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 59 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 58 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 55 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 54 | suppressed |
| Gemtesa | Vibegron | 53 | suppressed |
| Lamotrigine | Lamotrigine | 50 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 48 | 12 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 47 | suppressed |
| Latanoprost | Latanoprost | 47 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 45 | 28 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 45 | suppressed |
| Movantik | Naloxegol Oxalate | 44 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 44 | suppressed |
| Clozapine | Clozapine | 43 | suppressed |
| Atenolol | Atenolol | 42 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 42 | suppressed |
| Fentanyl | Fentanyl | 42 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 42 | suppressed |
| Invokana | Canagliflozin | 39 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 39 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 38 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 37 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 36 | suppressed |
| Methotrexate | Methotrexate Sodium | 36 | suppressed |
| Prednisone | Prednisone | 36 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 36 | suppressed |
| Acetazolamide | Acetazolamide | 35 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 35 | 15 |
| Lacosamide | Lacosamide | 35 | suppressed |
| Ztlido | Lidocaine | 34 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 33 | 23 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 33 | 24 |
| Butrans | Buprenorphine | 32 | suppressed |
| Myrbetriq | Mirabegron | 32 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 31 | suppressed |
| Cephalexin | Cephalexin | 31 | 21 |
| Oxycontin | Oxycodone Hcl | 31 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 30 | 16 |
| Midodrine Hcl | Midodrine Hcl | 30 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 29 | suppressed |
| Allopurinol | Allopurinol | 29 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 29 | suppressed |
| Paliperidone Er | Paliperidone | 29 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 28 | suppressed |
| Azithromycin | Azithromycin | 28 | 28 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 28 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 28 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 28 | suppressed |
| Acetazolamide Er | Acetazolamide | 27 | suppressed |
| Bupropion Xl | Bupropion Hcl | 27 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 27 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 26 | 17 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 25 | 13 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 25 | 13 |
| Methylprednisolone | Methylprednisolone | 25 | 23 |
| Enoxaparin Sodium | Enoxaparin Sodium | 24 | suppressed |
| Lovastatin | Lovastatin | 24 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 24 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 24 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 24 | suppressed |
| Acetic Acid | Acetic Acid | 23 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 23 | 12 |
| Novolog Flexpen | Insulin Aspart | 23 | suppressed |
| Nucynta | Tapentadol Hcl | 23 | suppressed |
| Olanzapine Odt | Olanzapine | 23 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 23 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 23 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 22 | 18 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 22 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 22 | suppressed |
| Carbamazepine Er | Carbamazepine | 21 | suppressed |
| Chlorthalidone | Chlorthalidone | 21 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 21 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 21 | suppressed |
| Lyrica | Pregabalin | 21 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 21 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 21 | suppressed |
| Ezetimibe | Ezetimibe | 20 | suppressed |
| Glimepiride | Glimepiride | 20 | suppressed |
| Hydroxyurea | Hydroxyurea | 20 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 20 | suppressed |
| Aptiom | Eslicarbazepine Acetate | 19 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 19 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 19 | suppressed |
| Ondansetron Odt | Ondansetron | 19 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 19 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 18 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 18 | 12 |
| Zolpidem Tartrate | Zolpidem Tartrate | 18 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 17 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 17 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 17 | suppressed |
| Verquvo | Vericiguat | 17 | suppressed |
| Enulose | Lactulose | 16 | suppressed |
| Lactulose | Lactulose | 16 | suppressed |
| Digoxin | Digoxin | 15 | suppressed |
| Haloperidol | Haloperidol | 15 | suppressed |
| Humulin R | Insulin Regular, Human | 15 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 14 | suppressed |
| Diclofenac Epolamine | Diclofenac Epolamine | 14 | suppressed |
| Folic Acid | Folic Acid | 14 | suppressed |
| Nifedipine Er | Nifedipine | 14 | suppressed |
| Phenytoin | Phenytoin | 14 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Topiramate | Topiramate | 13 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 13 | suppressed |
| Vtama | Tapinarof | 13 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 12 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 12 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 12 | suppressed |
| Nystatin | Nystatin | 12 | 11 |
| Rivastigmine | Rivastigmine | 12 | suppressed |
| Admelog Solostar | Insulin Lispro | 11 | suppressed |
| Alprazolam | Alprazolam | 11 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 11 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 11 | suppressed |
| Levofloxacin | Levofloxacin | 11 | suppressed |
| Metaxalone | Metaxalone | 11 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 11 | suppressed |
| Valsartan | Valsartan | 11 | suppressed |
| Vyzulta | Latanoprostene Bunod | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $355.41 · 12 records | VERTEX PHARMACEUTICALS INCORPORATED | ETERNA, JOURNAVX, QULIPTA, UBRELVY, WaveWriter Alpha Prime 16 | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error